ABUS vs DEO · P/E 5.4, rev $6.2M vs P/E 16, $55.86B cap
Arbutus Biopharma Corp (ABUS) versus Diageo PLC ADR (DEO) — a side-by-side from cached financials, not a winner call.
Arbutus Biopharma Corp (ABUS) is a biotechnology company listed on NASDAQ.
Diageo PLC ADR (DEO) is a beverages - wineries & distilleries company listed on US.
Latest reported ABUS revenue for 2024-12-31 was $6.2M. Net income was -$69.9M. Revenue was down 66.0% from 2023-12-31 to 2024-12-31. ABUS currently screens at market cap $883.0M and trailing P/E 5.4.
DEO does not have a complete income-statement cache yet.
ABUS currently screens at market cap $883.0M and trailing P/E 5.4. DEO currently screens at market cap $55.86B and trailing P/E 15.6.
Not investment advice. Open the ABUS and DEO stock pages for the full models.
Not investment advice.